Compare Crispr Therapeutics AG (CRSP) vs Harley-Davidson Inc (HOG) Price & Performance

CRISPR Therapeutics (CRSP) trades at $50.44, down 6.59% over 24 hours amid bearish technical signals. The company shows negative profitability metrics with -4,101.26% net income margin and -$581.60M net loss for 2025, though Q2 2026 EPS beat expectations. Recent news highlights upcoming clinical data presentations and commercial progress with CASGEVY gene therapy. Cash flow remains negative from operations but positive overall due to financing activities.

While analyst consensus remains bullish with 57.9% buy ratings and $67.83 price target, significant execution risks persist. The stock faces pressure from sustained cash burn and competitive threats, but potential catalysts include upcoming clinical data readouts and CASGEVY revenue growth. Investors should weigh high-risk biotech volatility against breakthrough therapy potential.

Harley-Davidson (HOG) trades at $26.75, down 0.71% on the day, with a bullish technical signal and mixed earnings history. The stock shows attractive valuation ratios, including a P/E of 14.97 and P/S of 0.72, but faces declining revenue and net income margins. Recent news highlights tariff exposure and a data breach, while analyst consensus is a 'Hold' with a $28.50 price target. Cash flow trends are volatile, with 2025 showing a net inflow of $1.35 billion driven by investing activities.

The outlook for HOG is cautious due to fundamental pressures, including falling profitability and revenue, offset by low valuations and a dividend. Key risks include competitive threats and sensitivity to tariffs. Upside potential exists if the 'Back to the Bricks' strategy revives growth, but investors should weigh margin erosion against valuation support.